CD274 and neoplasm: The relative tumor volume was profoundly decreased (71.2% ± 6.0% vs. 39.1% ± 8.6%, respectively, p < 0.001, Figure 6A), and survival times were prolonged (Figure 6C, median survival in days: 34 vs. 50 days, respectively, log-rank test, p < 0.001) in the DAC with the PD-L1 blockade group compared to the PBS with the PD-L1 blockade group.